Clinical Trials Directory

Trials / Completed

CompletedNCT04915781

Tobacco Use and COVID-19 Incidence in the Finnish General Population

Tobacco Use and Incidence of SARS-CoV-2 Infection in the Finnish General Population

Status
Completed
Phase
Study type
Observational
Enrollment
60,872 (actual)
Sponsor
Finnish Institute for Health and Welfare · Other Government
Sex
All
Age
20 Years
Healthy volunteers
Accepted

Summary

This is an observational study of participants in three general population health surveys (FinSote 2018, 2019, 2020) who are followed up until the incidence of SARS-CoV-2 infection or end of follow-up. The primary objective is to examine the association between tobacco use and the risk of SARS-CoV-2 infection in a general population sample in Finland.

Detailed description

Tobacco use, as a leading risk factor of death and disability due to respiratory diseases, was expected to increase the risk of SARS-CoV-2 infection and COVID-19 deaths. Earlier epidemiological studies, however, showed that smokers were underrepresented among patients hospitalized due to COVID-19. The most recent meta-analysis has confirmed these early findings, showing that current smokers had lower risk of SARS-CoV-2 infection than never smokers (Relative risk 0.71, 95% Credible interval 0.61; 0.82). A majority of these studies are based on samples of hospitalized patients, tested population or specific population groups, which might not represent the general population. In addition, data on tobacco use has been primarily collected from electronic health records or retrospectively and therefore prone to misclassification and information bias. A message of a protective effect of tobacco use could undermine public health efforts to curb its use and reduce the perception of harm in the general population. Studies with general population samples and prospective data collection are thus urgently needed. The aim of the study is to examine the association between tobacco use and the risk of SARS-CoV-2 infection. We will explore several forms of tobacco use (smoking, moist smokeless tobacco and e-cigarettes) and investigate whether introducing a potential collider bias by adjusting for mediating risk factors (alcohol use, physical activity and obesity) could have explained earlier results. We will use data from a prospective cohort study of nationally representative health surveys in Finland linked to SARS-CoV-2 incidence data, which is less subject to collider and recall bias than previous case-control studies.

Conditions

Interventions

TypeNameDescription
OTHERNot applicable, this is an observational studyNot applicable, this is an observational study

Timeline

Start date
2017-10-02
Primary completion
2021-12-30
Completion
2021-12-30
First posted
2021-06-07
Last updated
2022-06-22

Locations

1 site across 1 country: Finland

Source: ClinicalTrials.gov record NCT04915781. Inclusion in this directory is not an endorsement.